Roche Molecular Systems, Inc. v. Foresight Diagnostics Inc.

Summary

The United States District Court for the Northern District of California partially granted and partially denied Foresight Diagnostics Inc.’s motion to dismiss Roche’s first amended complaint. The court dismissed without prejudice Roche’s Delaware trade secret, California unfair competition, and Delaware common-law unfair competition claims, while allowing its federal and California trade secret claims and declaratory judgment claim to proceed. The court concluded that the claims were not time-barred at the pleading stage and that Roche plausibly identified trade secrets and alleged misappropriation by Foresight.

Holdings

1. The allegations did not establish on the face of the amended complaint that publication of the Chabon 2020 article placed Roche on actual or inquiry notice of the alleged misappropriation, so dismissal of the DTSA and CUTSA claims as time-barred was unwarranted.
2. Roche plausibly identified its alleged trade secrets with sufficient particularity to distinguish them from matters of general knowledge in the trade.
3. Roche plausibly alleged that Foresight misappropriated Roche's trade secrets, including indirectly through its co-founders, and therefore stated DTSA and CUTSA claims against Foresight.
4. Roche stated a plausible declaratory-judgment claim because its allegations established a substantial controversy between parties with adverse legal interests concerning ownership of the disputed patent applications.
5. The court declined to incorporate Stanford's policies by reference because the amended complaint did not refer to them extensively and Foresight offered them primarily to dispute Roche's well-pleaded allegations.

Questions Presented

1. Whether Roche's DTSA and CUTSA trade-secret misappropriation claims were barred by the applicable three-year statute of limitations at the pleading stage.
2. Whether Roche adequately identified its alleged trade secrets with sufficient particularity.
3. Whether Roche plausibly alleged that Foresight misappropriated Roche's trade secrets, including through its co-founders.
4. Whether Roche stated a justiciable declaratory-judgment claim concerning ownership of disputed patent applications.
5. Whether the court could incorporate Stanford's patent-ownership policies by reference and rely on them to defeat Roche's well-pleaded allegations at the motion-to-dismiss stage.

Disposition

other